{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:31:52Z","timestamp":1792067512138,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008889","name":"UBE Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008889","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018289","name":"The Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaccao.2024.10.011","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:04:40Z","timestamp":1733857480000},"page":"38-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy"],"prefix":"10.1016","volume":"7","author":[{"given":"Yoshihide","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Suetomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Uchinoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2024.10.011_bib1","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.10.011_bib2","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2024.10.011_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.jaccao.2024.10.011_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2024.10.011_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.RES.76.4.645","article-title":"Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium","volume":"76","author":"Wang","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2024.10.011_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.yjmcc.2011.07.016","article-title":"CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes","volume":"51","author":"Sag","year":"2011","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tox.2013.04.016","article-title":"Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity","volume":"309","author":"Sishi","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.jaccao.2024.10.011_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ncpcardio0419","article-title":"Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia","volume":"3","author":"Yano","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2024.10.011_bib9","doi-asserted-by":"crossref","first-page":"d671","DOI":"10.2741\/ikemoto","article-title":"Regulation of calcium release by interdomain interaction within ryanodine receptors","volume":"7","author":"Ikemoto","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.jaccao.2024.10.011_bib10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jacc.2009.01.065","article-title":"Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor","volume":"53","author":"Kobayashi","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126112","article-title":"Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Nakamura","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaccao.2024.10.011_bib12","article-title":"Dantrolene prevents hepatic steatosis by reducing cytoplasmic Ca2+ level and ER stress","volume":"23","author":"Tamitani","year":"2020","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.jaccao.2024.10.011_bib13","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1038\/s41598-021-86822-x","article-title":"Enhancing calmodulin binding to ryanodine receptor is crucial to limit neuronal cell loss in Alzheimer disease","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2024.10.011_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/emm.2006.63","article-title":"Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes","volume":"38","author":"Kim","year":"2006","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jaccao.2024.10.011_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.114.093849","article-title":"Adverse effects of doxorubicin and its metabolic product on cardiac RYR2 and SERCA2A","volume":"86","author":"Hanna","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tranon.2019.12.006","article-title":"Dantrolene attenuates cardiotoxicity of doxorubicin without reducing its antitumor efficacy in a breast cancer model","volume":"13","author":"Todorova","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.hroo.2021.08.008","article-title":"Cardioprotective effects of dantrolene in doxorubicin-induced cardiomyopathy in mice","volume":"2","author":"Azam","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.jaccao.2024.10.011_bib18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.0000121354.34067.48","article-title":"Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure","volume":"109","author":"Delgado","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.10.011_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.106.652339","article-title":"Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin","volume":"116","author":"Neilan","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.10.011_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/CIRCRESAHA.109.209312","article-title":"Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor","volume":"106","author":"Uchinoumi","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2024.10.011_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-001-0392-4","article-title":"Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma","volume":"49","author":"Hempel","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","article-title":"Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass","volume":"41","author":"Barpe","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jaccao.2024.10.011_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jphotobiol.2017.03.024","article-title":"Fluorescence properties of doxorubicin in PBS buffer and PVA films","volume":"170","author":"Shah","year":"2017","journal-title":"J\u00a0Photochem Photobiol B"},{"key":"10.1016\/j.jaccao.2024.10.011_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41586-019-1377-y","article-title":"Modulation of cardiac ryanodine receptor 2 by calmodulin","volume":"572","author":"Gong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2024.10.011_bib25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.hrthm.2022.02.003","article-title":"Stabilization of RyR2 maintains right ventricular function, reduces the development of ventricular arrhythmias, and improves prognosis in pulmonary hypertension","volume":"19","author":"Tanaka","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2024.10.011_bib26","first-page":"82","article-title":"Doxorubicin disrupts the calcium homeostasis through its antagonistic activity on PINK1\u2014an in-silico approach","volume":"13","author":"Mohan","year":"2023","journal-title":"Biointerface Res Appl Chem"},{"key":"10.1016\/j.jaccao.2024.10.011_bib27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCRESAHA.115.307604","article-title":"Chemical endoplasmic reticulum chaperone alleviates doxorubicin-induced cardiac dysfunction","volume":"118","author":"Fu","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2024.10.011_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaccao.2024.10.011_bib29","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1083\/jcb.141.6.1423","article-title":"The regulation of reactive oxygen species production during programmed cell death","volume":"141","author":"Tan","year":"1998","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2023.102778","article-title":"Calcium as a master regulator of ferroptosis and other types of regulated necrosis","volume":"114","author":"Pedrera","year":"2023","journal-title":"Cell Calcium"},{"key":"10.1016\/j.jaccao.2024.10.011_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1083\/jcb.139.5.1317","article-title":"Requirement for cGMP in nerve cell death caused by glutathione depletion","volume":"139","author":"Li","year":"1997","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jaccao.2024.10.011_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ceca.2017.05.007","article-title":"The role of Ca2+ in cell death caused by oxidative glutamate toxicity and ferroptosis","volume":"70","author":"Maher","year":"2018","journal-title":"Cell Calcium"},{"key":"10.1016\/j.jaccao.2024.10.011_bib33","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.10.011_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/ph16030391","article-title":"Exposure to doxorubicin modulates the cardiac response to isoproterenol in male and female mice","volume":"16","author":"Agostinucci","year":"2023","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087324003727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087324003727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T14:54:07Z","timestamp":1737730447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087324003727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666087324003727"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.10.011","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}